N-heterocyclic inhibitors of TNF-alpha expression
US8044040B2 · kind B2 · utility
6Cited by
6References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 16, 2007 |
| Grant date | Oct 25, 2011 |
| Priority date | — |
| Expiry date | Jun 30, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I):Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.